Core Viewpoint - The company, Jinxin Reproductive Medicine (01951), anticipates a loss of no more than RMB 1.09 billion in the first half of 2025, following a profit of approximately RMB 190 million in the first half of 2024, primarily due to impairment and provisions related to goodwill, intangible assets, and other financial assets in its operations in the United States and Laos [1] Group 1 - The expected loss for the first half of 2025 is mainly attributed to the recognition of impairment and provisions for certain goodwill, intangible assets, and other financial assets [1] - The company has conducted a careful assessment of its operational and financial performance, as well as the future prospects of its business, to determine the need and extent of the impairment and provisions [1] - The actual amounts of impairment and provisions will require further evaluation by the company before they can be finalized [1] Group 2 - The company believes that the impairment and provisions in the first half of 2025 will not have a significant adverse impact on its overall business operations and cash flow, as they are primarily one-time non-cash items [1] - Despite challenges posed by the macroeconomic and industry conditions in the first half of 2025, the company remains confident in the long-term prospects of the industry and its growth due to its solid industry foundation and ongoing efforts to enhance clinical outcomes, patient care, and service quality [1]
锦欣生殖(01951)发盈警 预计中期亏损不超10.9亿元